YS-49
Based on 17 publication(s) in Google Scholar
YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.98%
- CAS. Nr.: 132836-42-1
- Formel: C20H20BrNO2
- Molecular Weight:386.28
-
Speicherung:
4°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) YS-49
More- Signal Transduct Target Ther. 2021 Jun 18;6(1):234. [Abstract]
- Sci China Life Sci. 2025 Mar;68(3):746-763. [Abstract]
- Mol Ther Oncolytics. 2022 Aug 5:26:360-371. [Abstract]
- Mater Des. 2026 May 30;267:116311.
- Front Immunol. 2021 Oct 15;12:699478. [Abstract]
- J Ethnopharmacol. 2026 Jul 15:366:121662. [Abstract]
- Biochem Pharmacol. 2024 May:223:116112. [Abstract]
- Pharm Biol. 2023 Dec;61(1):541-555. [Abstract]
- Commun Biol. 2026 Jan 23;9(1):311. [Abstract]
- Mol Med Rep. 2025 Apr;31(4):95. [Abstract]
- Sci Rep. 2023 Sep 12;13(1):15036. [Abstract]
- Cancers (Basel). 2022 Jun 21;14(13):3039. [Abstract]
- J Anim Sci. 2025 Jan 4:103:skaf266. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- BMC Musculoskelet Disord. 2025 Oct 14;26(1):961. [Abstract]
- Int J Rheum Dis. 2024 Jun 22.
- SSRN. 2026 Mar 10.
Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen
MoreAlle Adrenergic Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Platelet | IC50 |
0.38 μM
Compound: 2S, (S)-(-)-YS-49
|
Inhibition of epinephrine-induced platelet aggregation in rat blood
Inhibition of epinephrine-induced platelet aggregation in rat blood
|
[PMID: 18556200] |
| Platelet | IC50 |
16 μM
Compound: 2S, (S)-(-)-YS-49
|
Inhibition of U46619-induced platelet aggregation in rat blood
Inhibition of U46619-induced platelet aggregation in rat blood
|
[PMID: 18556200] |
| Platelet | IC50 |
270 μM
Compound: 2S, (S)-(-)-YS-49
|
Inhibition of ADP-induced platelet aggregation in rat blood
Inhibition of ADP-induced platelet aggregation in rat blood
|
[PMID: 18556200] |
| Platelet | IC50 |
5.6 μM
Compound: 2S, (S)-(-)-YS-49
|
Inhibition of NaAA-induced platelet aggregation in rat blood
Inhibition of NaAA-induced platelet aggregation in rat blood
|
[PMID: 18556200] |
| Platelet | IC50 |
69 μM
Compound: 2S, (S)-(-)-YS-49
|
Inhibition of collagen-induced platelet aggregation in rat blood
Inhibition of collagen-induced platelet aggregation in rat blood
|
[PMID: 18556200] |
YS-49 (1-100?μM; 18 hours; RAVSMC and RAW 264.7 cells) concentration-dependently inhibits the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to lipopolysaccharide (LPS) plus INF-γ, with IC50 values of 22 μM and 30?μM, respectively[2].
YS-49 (10-100?μM; 18 hours; RAVSMC and RAW 264.7 cells) suppresses iNOS gene expression induced by LPS and/or cytokines in RAVSMC and RAW 264.7 cells at the transcriptional level[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAVSMC and RAW 264.7 cells
-
Concentration:10 μΜ, 30 μΜ and 100 μΜ (RAVSMC cells); 1 μΜ, 10 μΜ and 100 μM (RAW 264.7 cells)
-
Incubation Time:18 hours
-
Result:Inhibited the accumulation of nitrite in both RAVSMC and RAW 264.7 exposed to LPS+INF-γ, with IC50 values of 22 and 30 μM, respectively.
-
Cell Line:RAVSMC and RAW 264.7 cells
-
Concentration:10 μΜ, 30 μΜ and 100 μΜ
-
Incubation Time:18 hours
-
Result:Concentration-dependently inhibited the expression of iNOS protein induced by LPS plus IFN-γ.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague Dawley rats (250-300 g)[2]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; 8 hours
-
Result:Serum NOx levels were significantly reduced.
Chemical Information
-
CAS. Nr. 132836-42-1
-
Appearance Solid
-
Molecular Weight 386.28
-
Formel C20H20BrNO2
-
Color White to off-white
-
SMILES
OC1=CC2=C(C(CC3=C4C=CC=CC4=CC=C3)NCC2)C=C1O.[H]Br
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. [Abstract]2021 Jun 18;6(1):234. PMID: 34140465 -
Sci China Life Sci
Integrating spatial transcriptomics and single-nucleus RNA-seq revealed the specific inhibitory effects of TGF-β on intramuscular fat deposition. [Abstract]2025 Mar;68(3):746-763. PMID: 39422812 -
Mol Ther Oncolytics
2022 Aug 5:26:360-371. PMID: 36090473 -
-
Front Immunol
"γδT Cell-IL17A-Neutrophil" Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy. [Abstract]2021 Oct 15;12:699478. PMID: 34721375 -
J Ethnopharmacol
Huangqin Qingre Chubi Capsule modulates the lncRNA AP005432.1/PI3K/AKT axis and is associated with improved self-perception of patients and inflammation in ankylosing spondylitis. [Abstract]2026 Jul 15:366:121662. PMID: 41956229 -
Biochem Pharmacol
Columbianadin suppresses glioblastoma progression by inhibiting the PI3K-Akt signaling pathway. [Abstract]2024 May:223:116112. PMID: 38458331 -
Pharm Biol
Chinese herbal compound Huangqin Qingrechubi capsule reduces lipid metabolism disorder and inflammatory response in gouty arthritis via the LncRNA H19/APN/PI3K/AKT cascade. [Abstract]2023 Dec;61(1):541-555. PMID: 36994890 -
Commun Biol
DTX1-mediated degradation of TUBB3 in Kupffer cells mitigates hepatocellular carcinoma progression by regulating M1/M2 polarization. [Abstract]2026 Jan 23;9(1):311. PMID: 41577987 -
Mol Med Rep
Mechanism of β‑sitosterol in treating keloids: Network pharmacology, molecular docking and experimental verification. [Abstract]2025 Apr;31(4):95. PMID: 39981895 -
Sci Rep
The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes. [Abstract]2023 Sep 12;13(1):15036. PMID: 37699930 -
Cancers (Basel)
2022 Jun 21;14(13):3039. PMID: 35804814 -
J Anim Sci
Roles of JNK, ERK, and PI3K/AKT signaling pathways in zinc-mediated alleviation of thermal stress-induced damage to the integrity and barrier function of primary cultured chick jejunal epithelial cells. [Abstract]2025 Jan 4:103:skaf266. PMID: 40795135 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
BMC Musculoskelet Disord
YS-49 activates the PI3K/AKT signaling pathway in MC3T3-E1 cells to enhance osteoblast differentiation and inhibits glucocorticoid-induced bone loss in vivo. [Abstract]2025 Oct 14;26(1):961. PMID: 41088103 -
-
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (258.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 10 mg/mL (25.89 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (284 KB)
-
SDS (536 KB)
- English - EN (536 KB)
- Français - FR (536 KB)
- Deutsch - DE (536 KB)
- Norwegian - NO (536 KB)
- Español - ES (536 KB)
- Swedish - SV (536 KB)
- Italian - IT (536 KB)
- Korean - KR (536 KB)
- Portuguese - PT (536 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Sun JJ, Kim HJ, Seo HG, et al. YS49,1-(alpha-naphtylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,regulates angiotensin II-stimulated ROS production, JNK phosphorylation and vascular smooth muscle cell proliferation via the induction of heme oxygenase-1. Life Sci. 2008;82(11-12):600-7. [Content Brief]
[2]. Kang YJ, et al. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br J Pharmacol. 1999 Sep;128(2):357-64. [Content Brief]
[3]. Hsu YH, et al. RhoA-mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27. J Cell Physiol. 2014 Oct;229(10):1455-65. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.5888 mL | 12.9440 mL | 25.8880 mL | 64.7199 mL |
| 5 mM | 0.5178 mL | 2.5888 mL | 5.1776 mL | 12.9440 mL | |
| 10 mM | 0.2589 mL | 1.2944 mL | 2.5888 mL | 6.4720 mL | |
| 15 mM | 0.1726 mL | 0.8629 mL | 1.7259 mL | 4.3147 mL | |
| 20 mM | 0.1294 mL | 0.6472 mL | 1.2944 mL | 3.2360 mL | |
| 25 mM | 0.1036 mL | 0.5178 mL | 1.0355 mL | 2.5888 mL | |
| DMSO | 30 mM | 0.0863 mL | 0.4315 mL | 0.8629 mL | 2.1573 mL |
| 40 mM | 0.0647 mL | 0.3236 mL | 0.6472 mL | 1.6180 mL | |
| 50 mM | 0.0518 mL | 0.2589 mL | 0.5178 mL | 1.2944 mL | |
| 60 mM | 0.0431 mL | 0.2157 mL | 0.4315 mL | 1.0787 mL | |
| 80 mM | 0.0324 mL | 0.1618 mL | 0.3236 mL | 0.8090 mL | |
| 100 mM | 0.0259 mL | 0.1294 mL | 0.2589 mL | 0.6472 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
YS-49 Related Classifications
HY-15477 Related Classifications
Powered by Bioz